In conclusion, adjuvant treatment with trastuzumab is a tolerable and effective treatment when prescribed according to current clinical guidelines and praxis and confer a favorable prognosis for patients with HER2-postive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.